Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31322451 | 1.00 | OPRL1 (0.56) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| Hydrochloric Acid SCHEMBL4818869 | 0.98 | OPRL1 (0.54) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| Hydrochloric Acid SCHEMBL23411250 | 0.97 | OPRL1 (0.53) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL8086617 | 0.91 | OPRL1 (0.50) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL31557722 | 0.88 | OPRL1 (0.62) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL15689691 | 0.87 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| Tert-Butyl Formate SCHEMBL28790580 | 0.86 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1DRD2 | |
| SCHEMBL30227020 | 0.85 | OPRL1 (0.59) | OPRL1OPRM1OPRK1OPRD1NPC1 | |
| SCHEMBL26706222 | 0.85 | OPRL1 (0.59) | OPRL1OPRM1OPRK1OPRD1NPC1 | |
| SCHEMBL18767237 | 0.83 | OPRL1 (0.61) | OPRL1OPRM1OPRK1OPRD1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| US-4556656-A | HYPOTENSIVE, ANTIPSYCHOTIC, DIABETIC, AND ANALGESIC AGENTS | THE UPJOHN COMPANY (US) | 1985-12-03 | — | — | US | claimed |
| US-4284638-A | Pharmaceutical compositions with central depressant and antipsychotic activity having a butyrophenone derivative which is substituted in the 4-position and a C-(2-benzofuranyl)-piperidine or C-(2-benzofuranyl)-tetrahydro-pyridine | CIBA-GEIGY CORPORATION (US) | 1981-08-18 | — | — | US | claimed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| CN-119497615-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| WO-2024012554-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | 上海日馨医药科技股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| US-4179510-A | ISOCHROMANS AND 2-BENZOXEPINS | THE UPJOHN COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-4166062-A | HYPOTENSIVE AGENTS, CNS, ANTIDEPRESSANTS | THE UPJOHN COMPANY (US) | 1979-08-28 | — | — | US | disclosed |
| US-4153612-A | 2-Benzoxepins | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4120969-A | ANALGETIC, ANTIDIARRHEAL ACTIVITY | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-10-17 | — | — | US | disclosed |
| US-4075346-A | CNS depressant γ-(secondary amino)-ortho-nitro-butyrophenones | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-02-21 | — | — | US | disclosed |
| US-4039670-A | BUTYROPHENONE COMPOUNDS AS PSYCHOTROPICS | SUMITOMO CHEMICAL CO., LTD. (JA) | 1977-08-02 | — | — | US | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
| US-RE28973-E | PARKINSON'S DISEASE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | OPRL1 4460/4885OPRM1 4717/4885OPRK1 2472/4885 |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | OPRL1 1467/4885OPRM1 2108/4885OPRK1 1862/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | OPRL1 4460/4885OPRM1 4717/4885OPRK1 2472/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | OPRL1 299/4885OPRM1 668/4885OPRK1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.